Denosumab
Denosumab
Immunoglobulin G2, anti-(human tumor necrosis factor ligand superfamily member 11 (human osteoclast differentiation factor)) (human monoclonal AMG162 heavy chain), disulfide with human monoclonal AMG162 light chain, dimer
Stoffgruppe
Osteoporosemittel
Halbwertszeit
6-52 Tage
Hämoperfusion
nein
Hämodialyse
nein
Präparate
XGEVA® 120 mg Injektionslösung
Denosumab